Chemical formula: C₁₂H₂₂CaO₁₄ Molecular mass: 430.372 g/mol PubChem compound: 9290
Calcium gluconate interacts in the following cases:
Systemic corticosteroids reduce calcium absorption.
Calcium and magnesium mutually antagonize their effects.
Combination with thiazide diuretics may induce hypercalcaemia as these medicinal products reduce renal calcium excretion.
Calcium may antagonise the effect of calcium antagonists (calcium channel blockers).
Co-administration of calcium and epinephrine attenuate epinephrine’s β-adrenergic effects in postoperative heart surgery patients.
The likelihood of hypercalcaemia is increased in pregnant women in whom calcium and vitamin D are co-administered. Epidemiological studies with calcium have shown no increase in the teratogenic hazard to the foetus if used in the doses recommended.
Calcium passes across the placental barrier and its concentration in foetal blood is higher than in maternal blood.
Calcium gluconate injection should not be used during pregnancy unless the clinical condition of the woman requires treatment with calcium gluconate injection. The administered dose should be carefully calculated, and the serum calcium level regularly evaluated in order to avoid hypercalcaemia, which may be deleterious for the foetus.
Although supplemental calcium may be excreted in breast milk, the concentration is unlikely to be sufficient to produce any adverse effect on the neonate.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from calcium gluconate injection therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
No data available.
None known.
Mild gastrointestinal disturbances have occurred rarely (eg constipation, diarrhoea).
Cardiac arrhythmias and bradycardia may also occur.
The frequency of undesirable effects listed below is defined using the following convention: Very common ≥1/10, Common ≥1/100 to <1/10, Uncommon ≥1/1,000 to <1/100, Rare ≥1/10,000 to <1/1,000, Very rare <1/10,000, Not known Frequency cannot be estimated from the available data.
Cardiovascular and other systemic undesirable effects are likely to occur as symptoms of acute hypercalcaemia resulting from intravenous overdose or too rapid intravenous injection. Their occurrence and frequency is directly related to the administration rate and the administered dose.
Not known: Bradycardia, cardiac arrhythmia.
Not known: Hypotension, vasodilatation, circulatory collapse (possibly fatal), flushing, mainly after too rapid injection.
Not known: Nausea, vomiting.
Not known: Heat sensations, sweating.
Rarely, severe, and in some cases fatal, adverse reactions have been reported in preterm and full-term newborns (aged <28 days) who had been treated with intravenous ceftriaxone and calcium.
Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in newborns is due to their low blood volume and the longer half-life of ceftriaxone compared with adults.
Not known: Calcinosis cutis, possibly followed by skin ablation and necrosis, due to extravasation, has been reported.
Reddening of skin, burning sensation or pain during intravenous injection may indicate accidental perivascular injection, which may lead to tissue necrosis.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
